You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

Investigational Drug Information for Famitinib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Famitinib?

Famitinib is an investigational drug.

There have been 48 clinical trials for Famitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.

There are twenty-five US patents protecting this investigational drug and three hundred and eighty international patents.

Recent Clinical Trials for Famitinib
TitleSponsorPhase
PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerFudan UniversityPhase 3
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.Fudan UniversityPhase 2
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.Fudan UniversityPhase 2

See all Famitinib clinical trials

Clinical Trial Summary for Famitinib

Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib

See all Famitinib clinical trials

US Patents for Famitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Famitinib ⤷  Try a Trial Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) ⤷  Try a Trial
Famitinib ⤷  Try a Trial Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis Genentech, Inc. (South San Francisco, CA) ⤷  Try a Trial
Famitinib ⤷  Try a Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.